Synthesis of methotrexate α,γ-bis(amides) and correlation of thermotropic and DPPC biomembrane interaction parameters with their anticancer activity

Drug Development Research

Volumn 44, Issue 2-3, 1998, Pages 62-69

  Puglisi, Giovanni ^a   Fresta, Massimo ^a   Pignatello, Rosario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anticancer activity; Differential scanning calorimetry; Membrane; Methotrexate; Prodrug

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; METHOTREXATE ALPHA,GAMMA BIS(TETRADECYLAMIDE); METHOTREXATE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SYNTHESIS; ENTHALPY; ENTROPY; GROWTH INHIBITION; MEMBRANE; PHOSPHOLIPID BILAYER;

EID: 0031658065     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199806/07)44:2/3<62::AID-DDR3>3.0.CO;2-8     Document Type: Article

References (26)

1. Antonjuk DJ, Boadle DK, Cheung HTA, Friedler ML, Gregory PM, Tattersall MHN (1989): α-Monoamides of methotrexate as potential prodrugs. Arzneim Forsch Drug Res 39:12-15.
2. Assaraf YG (1993): Characterization by flow cytometry and fluorescein-methotrexate labeling of hydrophilic and lipophilic antifolate resistance in cultured mammalian cells. Anticancer Drugs 4:535-544.
3. Bach D (1984): Calorimetric studies of model and natural biomembranes. In Chapman D (ed): Biomembrane Structure and Function, London: Macmillan Press, pp 1-41.
4. Bannwarth B, Labat L, Moride Y, Schaeverbeche T (1994): Methotrexate in rheumatoid arthritis. Update. Drugs 47:25-50.
5. Bartlett GR (1959): Phosphorous assay in column chromatography. J Biol Chem 234:466-468.
6. Castelli F, Puglisi G, Pignatello R, Gurrieri S (1989): Calorimetric studies of the interaction of 4-biphenylacetic acid and its β-cyclodextrin inclusion compound with lipid model membrane. Int J Pharm 52:115-121.
7. Dembo M, Sirotnak FM (1984): Membrane transport of folate compounds in mammalian cells. In Sirotnak FM et al. (eds): Folate Antagonists as Therapeutic Agents. Vol. 1. New York: Academic Press, pp 173-217.
8. Frei E III (1985): Curative cancer chemotherapy. Cancer Res 45:6523-6537.
9. Fresta M, Puglisi G, Pignatello R, Giovinazzo C (1992): Evaluation and optimization of liposomes as a delivery device for methotrexate. Pharmazie 47:926-929.
10. Fresta M, Ventura CA, Puglisi G (1995): Interaction of the fluoroquinolone antimicrobial agent ofloxacin with a biological membrane model. Acta Technol Legis Medicam 5:173-188.
11. Matthews DA, Alden RA, Bolin JT, Freer ST, Hamlin H, Xuong N, Kraut J, Poe M, Williams M, Hoogsteen K (1977): Dihydrofolate reductase: X-ray structure on the binary complex with methotrexate. Science 197:452-155.
12. Niethammer D, Jackson RC (1975): Changes of molecular properties associated with the development of resistance against methotrexate in human lymphoblastoid cells. Eur J Cancer 11:845-854.
13. Pignatello K, Sorrenti V, Spampinato G, Pecora T, Panico A, Di Giacomo C, Fresta M, Vanella A, Puglisi G (1996): Synthesis and preliminary in vitro screening of lipophilic α,γ-bis(amides) as potential prodrugs of methotrexate. Anticancer Drug Des 11:253-264.
14. Piper JR, Montgomery JA, Sirotnak FM, Chello PL (1982): Syntheses of α- and γ-substituted amides, peptides, and esters of methotrexate and their evaluation as inhibitors of folate metabolism. J Med Chem 25:182-187.
15. Puglisi G, Fresta M, La Rosa C, Ventura CA, Panico AM, Mazzone G (1992): Liposomes as a potential drug carrier for citicoline (CDP-choline) and the effect of formulation conditions on encapsulation efficiency. Pharmazie 47:211-215.
16. Puglisi G, Fresta M, Ventura CA, Mazzone G, Vandelli MA (1995): The interaction occurring between methotrexate and a lipid model membrane of DPPC. J Thermal Anal 44:1287-1299.
17. Rahman LKA, Chhabra SR (1988): The chemistry of methotrexate and its analogues. Med Res Rev 8:95-156.
18. Rosowsky A (1973): Methotrexate analogs. 2. A facile method of preparation of lipophilic derivatives of methotrexate and 3′,5′-dichloromethotrexate by direct esterification. J Med Chem 16:1190-1193.
19. Rosowsky A, Forsch R, Uren J, Wick M (1981a): Methotrexate analogues. 14. Synthesis of new γ-substituted derivatives as dihydrofolate reductase inhibitors and potential anticancer agents. J Med Chem 24:1450-1455.
20. Rosowsky A, Yu CS, Uren J, Lazarus H, Wick M (1981b): Methotrexate analogues. 13. Chemical and pharmacological studies on amide, hydrazide and hydroxamic acid derivatives of the glutamate side chain. J Med Chem 24:559-567.
21. Rosowsky A, Forsch RA, Yu CS, Lazarus H, Beardsley GP (1984): Methotrexate analogues. 21. Divergent influence of alkyl chain length on the dihydrofolate reductase affinity and cytotoxicity of methotrexate monoesters. J Med Chem 27:605-609.
22. Rosowsky A, Bader H, Radike-Smith M, Cucchi CA, Wick MM, Freisheim JH (1986): Methotrexate analogues. 28. Synthesis and biological evaluation of newγ-monoamides of aminopterin and methotrexate. J Med Chem 29:1703-1709.
23. Sirotnak FM, Chello PL, Piper JR, Montgomery JA, DeGraw JI (1979): Structural specificity of folate analog transport and binding to dihydropholate reductase in murine tumor and normal cells: Relevance to therapeutic efficacy. In Kislink RL, Brown GM (eds): Chemistry and Biology of Pteridines, New York: Elsevier, pp 597-608.
24. Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ (1981): Relative frequency and kinetic properties of transport defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res 41:4447-4452.
25. Weinstein GD, Frost P (1971): Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 103:33-38.
26. Westerhof GR, Schornagel JH, Kathmann I, Jackman AL, Rosowsky A, Forsch RA, Hynes JB, Boyle FT, Peters GJ, Pinedo HM, Jansen G (1995): Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: Correlates of molecular-structure and biological activity. Mol Pharmacol 48:459-471.